We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Short-term Peginterferon-Induced High Functional Cure Rate in Inactive Chronic Hepatitis B Virus Carriers With Low Surface Antigen Levels.
- Authors
Zeng, Qing-Lei; Yu, Zu-Jiang; Shang, Jia; Xu, Guang-Hua; Sun, Chang-Yu; Liu, Na; Li, Chun-Xia; Lv, Jun; Liu, Yan-Min; Liang, Hong-Xia; Li, Zhi-Qin; Pan, Ya-Jie; Hu, Qiu-Yue; Li, Wei; Zhang, Da-Wei; Wang, Fu-Sheng
- Abstract
Background None of the current guidelines recommend antiviral therapy for inactive hepatitis B virus (HBV) carriers (IHCs). Methods In this real-world, multicenter, nonrandomized study, 32 participants meeting the inclusion criteria were enrolled 1:1 for treatment with peginterferon α-2b or monitoring without treatment based on participant preference. The expected treatment duration was 48 weeks. The primary end point was hepatitis B surface antigen (HBsAg) loss. The HBV vaccine could be injected after HBsAg loss. Results All patients had HBsAg levels of <20 IU/mL. The mean baseline HBsAg levels were 6.6 IU/mL and 5.8 IU/mL in the treated and untreated groups, respectively. Fifteen (93.8%) participants achieved HBsAg loss, 5 obtained HBsAg seroconversion after undergoing a mean of 19.7 weeks of therapy in the treated group, and no one in the follow-up group achieved HBsAg loss during a mean follow-up time of 12.6 months (P <.0001). Generally, the therapy was well tolerated. Nine of 11 individuals who exhibited HBsAg loss benefited from receiving the HBV vaccine. Conclusions This study provides justification for further studies of short-course peginterferon α-2b for the functional cure of IHCs with low HBsAg levels. Additionally, HBV vaccine injection is beneficial after interferon-induced HBsAg loss.
- Subjects
HEPATITIS B virus; CHRONIC hepatitis B; HEPATITIS associated antigen; CELL surface antigens; HEPATITIS B vaccines
- Publication
Open Forum Infectious Diseases, 2020, Vol 7, Issue 6, p1
- ISSN
2328-8957
- Publication type
Article
- DOI
10.1093/ofid/ofaa208